New Safety Information Regarding Rituxan

December 19, 2006

On December 19, 2006, Genentech, Inc. issued a letter to inform all potential Rituxan® prescribers that Genentech and its collaborator, Biogen Idec, are working with the U.S. Food and Drug Administration (FDA) to update the Rituxan (rituximab) prescribing information to include additional safety information in the Warnings section of the label related to two reports of progressive multifocal eukoencephalopathy (PML) in patients with Systemic Lupus Erythematosus (SLE) treated with Rituxan.

Click here to access the "Dear Healthcare Provider letter.

Rituxan Safety Information Q&A

Rituxan Update - Update December 26, 2006

 

 

Email This Article To A Friend - Print This Article